July 2024 in “Journal of Investigative Dermatology” Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.
June 2024 in “British Journal of Dermatology” PRP with topical minoxidil is the most effective treatment for increasing hair density in androgenetic alopecia.
IL-18 signaling helps mature Tregs move into the thymus.
September 2023 in “Journal of the American Academy of Dermatology” Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.
1 citations
,
May 2025 in “The Journal of Dermatology” Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.
6 citations
,
April 2017 in “Experimental dermatology” CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.
3 citations
,
January 2022 in “Russian Medical Inquiry” Atopic dermatitis may trigger alopecia areata, and early treatment can help prevent severe cases.
2 citations
,
August 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Skin stem cells help create protective immune cells during wound healing.
25 citations
,
November 2020 in “Cell Reports Medicine” Developing human skin has immune cells with memory-like features.
2 citations
,
April 2024 in “Advanced Materials” A microneedle patch can help regrow hair by restoring immune balance in hair follicles.
IL-18 signaling helps mature Tregs move into the thymus.
Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
4 citations
,
May 2018 in “Journal of Neuro-Ophthalmology” New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
November 2022 in “Journal of Investigative Dermatology” Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.
May 2010 in “OPAL (Open@LaTrobe) (La Trobe University)” Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
January 2024 in “Wiadomości Lekarskie” Cell therapy is advancing with stem cell transplants and genetically modified cells improving treatment for diseases like cancer and autoimmune disorders.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
1 citations
,
October 2022 in “Molecular therapy” The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
March 2006 in “Drug Discovery Today: Therapeutic Strategies” The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.
46 citations
,
April 2020 in “Drugs” Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.
11 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
39 citations
,
May 2004 in “Clinics in Dermatology” The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.